+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Glenmark Pharmaceuticals Ltd (GLENMARK) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 59 Pages
  • September 2024
  • GlobalData
  • ID: 4282150
Glenmark Pharmaceuticals Ltd (GLENMARK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Glenmark Pharmaceuticals Ltd (Glenmark) focuses on the research, development, and manufacturing of branded, generic, and over the counter (OTC) pharmaceutical products. The company develops products for therapeutic areas including respiratory, dermatology, and oncology. It also has a presence in other therapeutic areas such as diabetes, cardiovascular and oral contraceptives. The company manufactures and supplies active pharmaceutical ingredients (APIs). Glenmark has manufacturing facilities in India, Argentina, the US, and Czech Republic. The company markets its products in North America, Japan, Latin America, Europe, India, Middle East North Africa (MENA), Asia and Russia, among others. Glenmark is headquartered in Mumbai, Maharashtra, India.

Glenmark Pharmaceuticals Ltd Key Recent Developments

  • Aug 14, 2024: Glenmark Pharmaceuticals Announces Financial Results for Quarter Ended June 30, 2024
  • Aug 14, 2024: Glenmark Pharma Reports Consolidated Revenue Growth of 6.9%, EBITDA Margin of 18.1% and PAT Margin of 10.5% YoY for Q1 FY 2024-25
  • May 24, 2024: Glenmark Pharma Reports Q4 FY2023-24 Financial results
  • Apr 29, 2024: Glenmark Pharmaceuticals receives ANDA approval for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Glenmark Pharmaceuticals Ltd - Key Facts
  • Glenmark Pharmaceuticals Ltd - Key Employees
  • Glenmark Pharmaceuticals Ltd - Key Employee Biographies
  • Glenmark Pharmaceuticals Ltd - Major Products and Services
  • Glenmark Pharmaceuticals Ltd - History
  • Glenmark Pharmaceuticals Ltd - Company Statement
  • Glenmark Pharmaceuticals Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Glenmark Pharmaceuticals Ltd - Business Description
  • Other Break-up: Other Operating Revenue
  • Performance
  • Other Break-up: Sale of Products
  • Performance
  • Other Break-up: Sale of Services
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Key Stats
  • Geographical Segment: India
  • Performance
  • Geographical Segment: Latin America
  • Performance
  • Geographical Segment: North America
  • Performance
  • Key Stats
  • R&D Overview
  • Glenmark Pharmaceuticals Ltd - Corporate Strategy
  • Glenmark Pharmaceuticals Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Glenmark Pharmaceuticals Ltd - Strengths
  • Glenmark Pharmaceuticals Ltd - Weaknesses
  • Glenmark Pharmaceuticals Ltd - Opportunities
  • Glenmark Pharmaceuticals Ltd - Threats
  • Glenmark Pharmaceuticals Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences, Power Financial Deals and Alliances
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Glenmark Pharmaceuticals Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Aug 14, 2024: Glenmark Pharmaceuticals Announces Financial Results for Quarter Ended June 30, 2024
  • Aug 14, 2024: Glenmark Pharma Reports Consolidated Revenue Growth of 6.9%, EBITDA Margin of 18.1% and PAT Margin of 10.5% YoY for Q1 FY 2024-25
  • May 24, 2024: Glenmark Pharma Reports Q4 FY2023-24 Financial results
  • Apr 29, 2024: Glenmark Pharmaceuticals receives ANDA approval for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC
  • Apr 01, 2024: Glenmark Pharmaceuticals Announces Board Changes
  • Feb 14, 2024: Glenmark Pharmaceuticals reports Consolidated Revenue of Rs. 29,096 Mn for Q3 FY 2023-24
  • Jan 30, 2024: Ichnos and Glenmark Take a Collaborative Leap to Accelerate Innovation in Cancer Treatment with Their Alliance - ‘Ichnos Glenmark Innovation'
  • Nov 10, 2023: Glenmark Pharma reports consolidated revenue growth of 6.3% and adjusted EBITDA growth of 8.3% YoY for Q2 FY 2023-24
  • Sep 27, 2023: Cosmo and Glenmark announce the signing of Distribution and License Agreements for Winlevi in Europe and South Africa
  • Aug 22, 2023: Glenmark Pharmaceuticals, USA Reaches Antitrust Settlement with DOJ
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Glenmark Pharmaceuticals Ltd, Key Facts
  • Glenmark Pharmaceuticals Ltd, Key Employees
  • Glenmark Pharmaceuticals Ltd, Key Employee Biographies
  • Glenmark Pharmaceuticals Ltd, Major Products and Services
  • Glenmark Pharmaceuticals Ltd, History
  • Glenmark Pharmaceuticals Ltd, Subsidiaries
  • Glenmark Pharmaceuticals Ltd, Joint Venture
  • Glenmark Pharmaceuticals Ltd, Key Competitors
  • Glenmark Pharmaceuticals Ltd, Ratios based on current share price
  • Glenmark Pharmaceuticals Ltd, Annual Ratios
  • Glenmark Pharmaceuticals Ltd, Interim Ratios
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Glenmark Pharmaceuticals Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Glenmark Pharmaceuticals Ltd, Performance Chart (2020 - 2024)
  • Glenmark Pharmaceuticals Ltd, Ratio Charts
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Sun Pharmaceutical Industries Ltd
  • Emcure Pharmaceuticals Ltd
  • Divi's Laboratories Ltd
  • Torrent Pharmaceuticals Ltd
  • ANI Pharmaceuticals Inc
  • Alkem Laboratories Ltd
  • Dr. Reddy's Laboratories Ltd
  • Viatris Inc
  • Pfizer Ltd India
  • Teva Pharmaceutical Industries Ltd
  • Aurobindo Pharma Ltd